Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients.

Jessica A SteadmanAhmer SultanCourtney N DayMarie A ParishSusanne G WarnerMichael L KendrickMark J TrutyZhaohui Jin Cornelius A Thiels

Published in: Journal of surgical oncology (2024)

PPI usage did not significantly influence mPR or OS following neoadjuvant fluoropyrimidine-based chemotherapy in resected PDAC patients. Further analysis of all patients, not just those who underwent resection, is required.

Keyphrases

neoadjuvant chemotherapy
end stage renal disease
locally advanced
lymph node
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
rectal cancer
patient reported outcomes
sentinel lymph node
radiation therapy
small molecule